COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02470585
Recruitment Status : Active, not recruiting
First Posted : June 12, 2015
Last Update Posted : May 4, 2020
Gynecologic Oncology Group
Australia New Zealand Gynaecological Oncology Group
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : May 3, 2019
Estimated Study Completion Date : December 8, 2026
Certification/Extension First Submitted : April 29, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 4, 2020